Biomarck is pleased to announce its inclusion on COVID-19 Drug Treatment Trackers: Milken Institute COVID-19 Treatment and Vaccine Tracker | Artis Ventures



Dr. Lumsden joined Biomarck as President and Chief Executive Officer in January 2021. He is a Non-Executive Director and the former CEO of Motif Bio where he raised $125 million, including two IPOs (AIM and NASDAQ), to advance iclaprim, a targeted antibacterial, through Phase 3 and NDA submission. Dr Lumsden previously founded and was the CEO of Tiemed LLC, a biotech company developing solutions for patients with difficulties taking oral medicines. Before that, Dr. Lumsden spent more than 10 years at Merck & Co., Inc., where he gained global experience in both the veterinary and human health markets, including worldwide businesses at Merck with annual revenues of more than $1 billion. Dr. Lumsden brings extensive domestic and international senior leadership experience in pharmaceuticals and biotechnology, including capital markets, corporate governance, new product launches, preclinical and clinical development, regulatory strategy, sales and marketing, business development, CMC and IP strategy. Dr. Lumsden received his Bachelor of Veterinary Medicine & Surgery from University of Edinburgh, U.K. and his Postgraduate Diploma in Marketing from the Chartered Institute of Marketing in the U.K.